Why AnaptysBio Trounced the Market on Thursday

AnaptysBio (NASDAQ: ANAB) rose by just over 11% on Thursday, as a high-profile bank has become more optimistic on the stock, to put it lightly.

J.P. Morgan analyst Anupam Rama upgraded his recommendation on AnaptysBio stock. In his estimation, it's now overweight (i.e., buy), from the previous underweight (sell). The analyst also more than doubled his price target on the shares to $40; it was formerly $19.

Image source: Getty Images.

Continue reading

Source Fool.com